Pradhan Anuradha, Ganguly Anasua, Naik Milind N, Nair Akshay Gopinathan, Desai Savari, Rath Suryasnata
Ophthalmic Plastic Surgery and Ocular Oncology Services, LV Prasad Eye Institute, MTC Campus, Bhubaneswar, Odisha, India.
Ophthalmic Plastic Surgery and Ocular Oncology Services, LV Prasad Eye Institute, KVC Campus, Vijayawada, Andhra Pradesh, India.
Indian J Ophthalmol. 2020 Aug;68(8):1609-1614. doi: 10.4103/ijo.IJO_1918_19.
To evaluate the current practice patterns in the treatment of thyroid eye disease (TED) in Indian subcontinent through a web-based survey of members of Oculoplastics Association of India (OPAI).
This was an online web-based questionnaire survey disseminated via monkeysurvey.com to all ratified active members of OPAI between May 1, 2016 and June 30, 2016. Questions encompassed the background, training, region, and experience of oculoplastic surgeons along with the management protocol of TED.
Of the 435 emails sent to OPAI members, 9 bounced and 180 (42.3%) responded within the study period. A large majority (96%) of respondents were oculoplastic surgeons practicing in India and the remaining practiced within South-East Asia. Two-thirds of respondents were oculoplastic surgeons with less than 10 years of clinical experience; 82% were fellowship trained in Oculoplasty. Almost all (99%) favored a multidisciplinary management of TED. A large majority routinely grade the severity (89%) and activity (87%) of disease before management. While corticosteroid remained the treatment of choice, 54% preferred immune-modulators as the second-line of therapy for recalcitrant TED. Three-quarters did not use orbital radiotherapy as a management modality in active TED owing to concerns over its efficacy and/or safety.
The survey gives useful insights to the practice patterns of TED management in Indian subcontinent. Multidisciplinary approach and grading of disease severity and activity were the rule rather than exception among OPAI members. Immune modulation was the preferred steroid-sparing agent in recalcitrant disease. Orbital radiotherapy was an uncommon treatment choice.
通过对印度眼整形协会(OPAI)成员进行基于网络的调查,评估印度次大陆甲状腺眼病(TED)的当前治疗模式。
这是一项基于网络的问卷调查,于2016年5月1日至2016年6月30日通过monkeysurvey.com分发给OPAI所有批准的活跃成员。问题涵盖眼整形外科医生的背景、培训、地区和经验以及TED的管理方案。
在发送给OPAI成员的435封电子邮件中,有9封被退回,180名(42.3%)在研究期间回复。绝大多数(96%)受访者是在印度执业的眼整形外科医生,其余的在东南亚执业。三分之二的受访者是临床经验少于10年的眼整形外科医生;82%接受过眼整形 fellowship培训。几乎所有(99%)的人都赞成对TED进行多学科管理。绝大多数人在治疗前常规对疾病的严重程度(89%)和活动度(87%)进行分级。虽然皮质类固醇仍然是首选治疗方法,但54%的人更喜欢将免疫调节剂作为难治性TED的二线治疗。四分之三的人由于担心其疗效和/或安全性,在活动性TED中不将眼眶放疗作为一种管理方式。
该调查为印度次大陆TED管理的实践模式提供了有用的见解。多学科方法以及对疾病严重程度和活动度进行分级在OPAI成员中是常规做法而非例外。在难治性疾病中,免疫调节是首选的类固醇替代药物。眼眶放疗是一种不常见的治疗选择。